Researchers in the UK and Germany are using drug repositioning to identify existing drugs that could treat spinal muscular atrophy (SMA).
We ve recently released an update to the SMA drug pipeline. This latest version includes: 20 active programs, including three approved therapies. 10 pharmaceutical partners. 12 programs in clinical trials. An ever-increasing breadth of potential treatment approaches to SMA. Effective Treatments for All Ages, Stages and Types of SMA The updated
therapy approved to treat SMA. Page 2. Pharmacy Management Drug Policy. Spinal Muscular Atrophy (SMA) – Spinraza (nusinersen) and Zolgensma.
This follows the roll-out of three transformative new SMA medicines Before 2024 there were no effective drugs for this condition
Cure SMA has invested more than $62 million in research and has funded half of all the ongoing new drug programs for SMA, including Spinraza, the first-ever treatment for SMA approved by the Food
Using this drug pipeline, we are tracking the progress of SMA treatments currently being tested in human clinical trials.
SMA patients treated with Zolgensma whose SMA; and risks and uncertainties associated with drug development and commercialization.
Make today a breakthrough. The SMA Drug Pipeline is how Cure SMA evaluates the success of our spinal muscular atrophy (SMA) research program.
Make today a breakthrough. Cure SMA shares a variety of different research-focused updates with our spinal muscular atrophy (SMA) community. Check out the various types of announcements below and visit Latest News for updates. View SMA Drug Pipeline Basic research grant awards Every spring, we announce the recipients of our
Spank!